Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution

Menon S, Davies A, Frentzas S, Hawkins CA, Segelov E, Day D, Markman B

(2022), Cancer Reports, 5(2), e1465

DOI: 101002/cnr21465

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M

(2022), Eur J Cancer, 165, 97-112

DOI: 101016/jejca202201017

18 F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy

Cherk MH, Nadebaum DP, Barber TW, Beech P, Haydon A, Yap KS

(2022), J MED IMAG RADIAT ON, 66(4), 483-94

DOI: 101111/1754-948513390

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ

(2022), Ann Oncol, 33(2), 169-80

DOI: 101016/jannonc202111002

Defining research and infrastructure priorities for cancer survivorship in Australia: a modified Delphi study

Crawford-Williams F, Koczwara B, Chan RJ, Vardy J, Lisy K, Morris J, Iddawela M, Mackay G, Jefford M

(2022), Support Care Cancer, 30(5), 3805-15

DOI: 101007/s00520-021-06744-2

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS

(2022), Clin Cancer Res, 28(1), 95-105

DOI: 101158/1078-0432CCR-21-1181

Implementing Optimal Care Pathways for Aboriginal and Torres Strait Islander People With Cancer: A Survey of Rural Health Professionals' Self-Rated Learning Needs

Ristevski E, Ludwick T, Leach M, Thompson S, Iddawela M, Pryce M, Wood E, Davidson K, Gell J

(2022), Int J Integr Care, 22(1), 27

DOI: 105334/ijic6028

Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study

Lin T, Pham J, Paul E, Conron M, Wright G, Ball D, Mitchell P, Atkin N, Brand M, Zalcberg J, Stirling RG

(2022), Lung Cancer, 163, 69-76

DOI: 101016/jlungcan202112006

1 2 3